NASDAQ · HURA
TuHURA Biosciences, Inc.
$1.90-$0.16 (-7.54%)
TuHURA Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.47% below the high.
Loading market information…
OTC · ALSE · USD
Stock price, earnings
Quote as of Jul 23, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Alseres Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Alseres Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Alseres Pharmaceuticals, Inc. focuses on creating both diagnostic and therapeutic solutions, with a primary emphasis on ailments affecting the central nervous system. Their flagship experimental compound is Altropane, a molecular imaging agent developed for identifying and diagnosing Parkinson's disease and dementia. Founded in 1972, the company was previously known as Boston Life Sciences, Inc. before officially changing its name to Alseres Pharmaceuticals, Inc. in June 2007. Its operations are headquartered in Auburndale, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:19 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.90-$0.16 (-7.54%)
TuHURA Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.47% below the high.
£6.34-£0.46 (-6.73%)
Hemogenyx Pharmaceuticals Plc’s quoted price sits in the lower half of its reported 52-week range, 48.01% below the high.
$1.16$0.00 (0.0%)
Evolva Holding S.A.’s quoted price sits in the lower half of its reported 52-week range, 32.16% below the high.
$0.01-$0.01 (-68.71%)
Lotus Ventures Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.29% below the high.
$0.00$0.00 (0.0%)
FluroTech Ltd.: Healthcare · Medical - Devices.
Achiko AG: Healthcare · Medical - Healthcare Information Services.
$0.00-$0.82 (-99.99%)
Phoenix Life Sciences International Limited: Healthcare · Drug Manufacturers - Specialty & Generic.
CA$0.02+CA$0.01 (+50.0%)
Aquarius Surgical Technologies Inc.’s quoted price sits in the upper half of its reported 52-week range, 25.0% below the high.
